PiepoliMFHoesAWAgewallS, et al.2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol2016; 23(11): NP1–NP96.
2.
ArnettDKBlumenthalRSAlbertMA, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol2019; 74(10): 1376–1414.
3.
TibautMCaprndaMKubatkaP, et al.Markers of atherosclerosis: part 2 – genetic and imaging markers. Heart Lung Circ2019; 28(5): 678–689.
4.
LyngbakkenMNMyhrePLRøsjøH, et al.Novel biomarkers of cardiovascular disease: applications in clinical practice. Crit Rev Clin Lab Sci2019; 56(1): 33–60.
5.
PetersenSEMatthewsPMFrancisJM, et al.UK Biobank's cardiovascular magnetic resonance protocol. J Cardiovasc Magn Reson2016; 18: 8.
6.
ArnoldNKoenigW. Is proteomics of value in cardiovascular risk assessment?. Curr Opin Lipidol2019; 30(6): 452–461.
7.
Frary CE, Kofoed Blicher M, Bastholm Olesen T, et al. Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals: from the MONICA 10 cohort. Eur J Prev Cardiol. 2020; 27: 570–578.
8.
PeterssonUÖstgrenCJBrudinL, et al.A consultation-based method is equal to SCORE and an extensive laboratory-based method in predicting risk of future cardiovascular disease. Eur J Cardiovasc Prev Rehabil2009; 16(5): 536–540.
9.
RoshandelGKhoshniaMPoustchiH, et al.Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet2019; 394(10199): 672–683.
10.
BramlagePSimsHMinguetJ, et al.The polypill: an effective approach to increasing adherence and reducing cardiovascular event risk. Eur J Prev Cardiol2017; 24(3): 297–310.
